From 1-phenyl-2-propylamine, selegiline hydrochloride, an anti-Parksins drug, was synthesized via N-methylation, enantiomer separation, N-alkylation and salt formation with an overall yield of 42.2%.
The invention provides a method for synthesizing (S)-N, N-dimethyl-3-hydroxyl-3-(2-thienyl) propylamine, and relates to a key intermediate of (S)-duloxetine.